TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02628600
Drug: LAI 590 mg
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
Study: NCT02628600
Drug: Multi-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug antimycobacterial regimen from study INS-212
Study: NCT00104728
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03880045
Drug: Topical TA
Normalized name: Doak 2% Topical Tar Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
Study: NCT04649216
Drug: PCO371
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCO371 Capsule
Study: NCT04649216
Drug: [14C]PCO371
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]PCO371 Oral solution
Study: NCT04649216
Drug: [14C]PCO371
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]PCO371 Solution for infusion
Study: NCT06090123
Drug: TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
Study: NCT04248712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains no active ingredient
Study: NCT03759639
Drug: IB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
Study: NCT00399568
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1 g/100 mL
Study: NCT00399568
Drug: IV Placebo 100 mL solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
Study: NCT02524236
Drug: Botox injection in the prostate
Normalized name: onabotulinumtoxinA Injection [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: transrectal access of prostatic injection
Study: NCT00861757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD (30 min after meal) for 12 weeks
Study: NCT03308968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study: NCT03998514
Drug: CB4211 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03998514
Drug: CB4211 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03998514
Drug: CB4211 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03998514
Drug: CB4211 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03998514
Drug: CB4211 Dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03998514
Drug: CB4211 Dose 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT03998514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT04256174
Drug: AK120 or placebo- Part 1- Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
Study: NCT04256174
Drug: AK120 or placebo- Part 1- Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
Study: NCT04256174
Drug: AK120 or placebo- Part 1- Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
Study: NCT04256174
Drug: AK120 or placebo- Part 1- Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
Study: NCT04256174
Drug: AK120 or placebo- Part 1- Cohort 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
Study: NCT04256174
Drug: AK120 or placebo- Part 2- Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
Study: NCT04256174
Drug: AK120 or placebo- Part 2- Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
Study: NCT04256174
Drug: AK120 or placebo- Part 2- Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
Study: NCT04256174
Drug: AK120 or placebo- Part 2- Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
Study: NCT02681653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equally matched placebo for 7 days to patients of septic shock admitted to ICU
Study: NCT01195818
Drug: RAS Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
Study: NCT04054206
Drug: MN-166
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
Study: NCT01589146
Drug: Heparin, Low-Molecular-Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks heparin prophylaxis
Study: NCT01527422
Drug: Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
Study: NCT00603941
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
Study: NCT01642901
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
Study: NCT01642901
Drug: normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
Study: NCT00864175
Drug: INCB007839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID
Study: NCT00864175
Drug: INCB007839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BID
Study: NCT00864175
Drug: INCB007839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg BID
Study: NCT00422188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intralipomal injection.
Study: NCT01135459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
Study: NCT02485509
Drug: VM-1500/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-1500 or Placebo
Study: NCT04073511
Drug: Samsoeum
Approvals — FDA: no, EMA: no, PMDA: no
Description: This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
Study: NCT04073511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
Study: NCT01771991
Drug: Topical Sodermix Dismutase in the form of Sodermix (SOD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
Study: NCT01771991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
Study: NCT00272831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet twice daily
Study: NCT01794507
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
Study: NCT00288574
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00288574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02078219
Drug: RDEA3170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT02078219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT02317601
Drug: placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05290506
Drug: Dipeptidyl-Peptidase IV Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
Study: NCT03226249
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04474197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-864 for oral administration.
Study: NCT02289196
Drug: Vx-006: 0,5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289196
Drug: Vx-006: 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289196
Drug: Vx-006: 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289196
Drug: Vx-006: 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04279119
Drug: ARQ-151- cream 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
Study: NCT02051751
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
Study: NCT00392834
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT00392834
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given IV
Study: NCT00392834
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT00392834
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given intrathecally
Study: NCT00392834
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: given intrathecally
Study: NCT03999099
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00659386
Drug: Intravenous immunoglobulin therapy
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
Study: NCT03394651
Drug: Oral medications to treat lower urinary tract symptoms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
Study: NCT00190229
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT00412958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of placebo
Study: NCT02620423
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
Study: NCT02620423
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
Study: NCT02188121
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
Study: NCT03748706
Drug: PTI-125, 100 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTI-125, 100 mg tablets taken twice a day for 28 days
Study: NCT04356846
Drug: LP-108 tablet
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally within 30 minutes after a meal at the designated dose, once daily.
Study: NCT03610516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses of placebo intravenous infusion
Study: NCT02994732
Drug: [14C]-BVD-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
Study: NCT00952861
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg QD in 5 days
Study: NCT00952861
Drug: Placebo (matching)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD i 5 days
Study: NCT00164008
Drug: zoledronic acid vs pamidronate
Normalized name: Pamidronic acid
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01938911
Drug: Syntocinon-Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU)
Study: NCT01288170
Drug: Nebcinal Tobi
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01288170
Drug: Tobi Nebcinal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02412189
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study: NCT00402324
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, capsules, by mouth every evening, daily, for 6 weeks.
Study: NCT04023383
Drug: 40 cc HyaRegen NCH gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
Study: NCT04023383
Drug: 40 cc sterile saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Study: NCT01938911
Drug: Placebo of syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal administration
Study: NCT00191399
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00122616
Drug: HIV antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
Study: NCT00637624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once every 3 weeks intravenous saline fluid
Study: NCT02466425
Drug: SHP465
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5mg and 25mg capsules (one capsule daily)
Study: NCT02466425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule that appear identical in size, weight, shape, color
Study: NCT02808325
Drug: Gelaspan 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelaspan 4% combined with Sterofundin ISO
Study: NCT02808325
Drug: Gelofusine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine 4% combined with Sodium Chloride
Study: NCT01072136
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
Study: NCT00112658
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00112658
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02534012
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
Study: NCT03107858
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Study: NCT03107858
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Study: NCT01111734
Drug: fMRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
Study: NCT03035864
Drug: rhNGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Drop 20 μg/mL
Study: NCT03098433
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT03098433
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator
Study: NCT03098433
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00460031
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg qam 10mg qhs
Study: NCT02564614
Drug: RO7070179
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
Study: NCT01802593
Drug: AZATHIOPRINE or METHOTREXATE
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
Study: NCT01802593
Drug: AZATHIOPRINE or METHOTREXATE
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks
Study: NCT00804050
Drug: infusion A: rEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
Study: NCT02505022
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
Study: NCT01637532
Drug: Carboplatin and Caelyx or doxorubicin
Normalized name: doxorubicin Injection [Caelyx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
Study: NCT02493361
Drug: pIL-12
Approvals — FDA: no, EMA: no, PMDA: no